The safety of 52 weeks of oral DHEA therapy for postmenopausal women

Maturitas

Volumn 63, Issue 3, 2009, Pages 240-245

  Panjari, Mary ^a   Bell, Robin J ^a   Jane, Fiona ^a   Adams, Jenny ^a   Morrow, Corallee ^a   Davis, Susan R ^a  

^a Central and Eastern Clinical School   (Australia)

Author keywords

DHEA; Endometrium; Glucose metabolism; Lipids; Menopause

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRASTERONE; TRIACYLGLYCEROL;

ACNE; ALOPECIA; ANDROGEN THERAPY; ARTICLE; BREAKTHROUGH BLEEDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; ENDOMETRIUM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA DISCHARGE; VOICE CHANGE;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOMETRIUM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; METRORRHAGIA; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 67649743512     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.03.020     Document Type: Article

References (27)

1. Panjari M., and Davis S.R. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 13 3 (2007) 239-248
2. Casson P.R., Santoro N., Elkind-Hirsch K., et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 70 1 (1998) 107
3. Villareal D., Holloszy J., and Kohrt W. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 53 5 (2000) 561-568
4. Arlt W., Callies F., and Allolio B. DHEA replacement in women with adrenal insufficiency-pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res 26 4 (2000) 505-511
5. Mortola J.F., and Yen S.S. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metabol 71 3 (1990) 696-704
6. Lasco A., Frisina N., Morabito N., et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 145 4 (2001) 457-461
7. Barnhart K.T., Freeman E., Grisso J.A., et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 84 11 (1999) 3896-3902
8. Labrie F., Diamond P., Cusan L., et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin Endocrinol Metab 82 10 (1997) 3498-3505
9. Stomati M., Monteleone P., Casarosa E., et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 14 5 (2000) 342-363
10. Genazzani A.D., Stomati M., Bernardi F., et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 80 6 (2003) 1495-1501
11. Panjari M., Bell R., Adams J., et al. Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women. J Womens Health (Larchmt) 17 10 (2008) 1559-1565
12. Morales A.J., Nolan J.J., Nelson J.C., and Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metabol 78 6 (1994) 1360-1367 [Erratum appears in J Clin Endocrinol Metab 1995 Sep;80(9):2799]
13. Legrain S., Massien C., Lahlou N., et al. Deyhydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in health elderly subjects. J Clin Endocrinol Metab 85 9 (2000) 3208-3217
14. Liu D., and Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277 24 (2002) 21379-21388
15. Friedewald W.T., Levy R.I., and Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
16. Labrie F., Belanger A., Belanger P., et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99 4-5 (2006) 182-188
17. Labrie F., Belanger A., Belanger P., et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 103 2 (2007) 178-188
18. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 7 (1985) 412-419
19. Davison S.L., Bell R., Donath S., Montalto J.G., and Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90 7 (2005) 3847-3853
20. Slowinska-Srzednicka J., Malczewska B., Srzednicki M., et al. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med 237 5 (1995) 465-472
21. Labrie F., Belanger A., Luu-The V., et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63 5-6 (1998) 322-328
22. Diamond P., Cusan L., Gomez J.L., Belanger A., and Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol Suppl. 150 (1996) S43-50
23. Arlt W., Callies F., Van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med 341 14 (1999) 1013
24. Cheng H.H., Hu X.J., and Ruan Q.R. Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol Sin (2008)
25. Darling G.M., Johns J.A., McCloud P.I., and Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 337 9 (1997) 595-601 [See comment]
26. Somboonporn W., Davis S., Seif M., and Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 4 (2005) CD004509
27. Labrie F., Luu-The V., Labrie C., et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24 (2003) 152